low - Healthcare diagnostics demonstrate defensive characteristics as cardiac monitoring is medically necessary rather than discretionary. However, moderate sensitivity exists through two channels: (1) employment-linked commercial insurance coverage affects patient volumes, with unemployment spikes reducing insured population, and (2) hospital and physician practice budgets can tighten during recessions, potentially delaying adoption of premium-priced monitoring solutions. Overall demand remains relatively stable through economic cycles as arrhythmia prevalence is age-driven rather than economically sensitive.

Rising interest rates create moderate headwinds through multiple channels. First, iRhythm's 6.01x debt/equity ratio means higher refinancing costs on the company's convertible debt (estimated $400M+ outstanding), directly impacting interest expense. Second, as a pre-profitable growth company trading at 6.7x sales, valuation multiples compress when risk-free rates rise as investors demand higher equity risk premiums. Third, higher rates can pressure healthcare system capital budgets, potentially slowing adoption of new diagnostic technologies. The company's negative free cash flow (-0.6% FCF yield) means it may need external financing, making credit conditions material.

growth - The stock attracts growth investors focused on healthcare innovation and market share expansion in a large addressable market (estimated $5B+ U.S. cardiac monitoring market). The 20.1% revenue growth, negative profitability, and 6.7x price/sales multiple indicate investors are paying for future earnings potential rather than current cash generation. The 30.6% one-year return despite recent volatility suggests momentum investors also participate during positive clinical or reimbursement catalysts. Not suitable for value or income investors given negative earnings, no dividend, and premium valuation.